|
[1]
|
WHO (2022) Fact-Sheet: Hepatitis B.
https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
|
|
[2]
|
张学高. 中国卫生健康统计年鉴2020[M]. 北京: 中国协和医科大学出版社, 2020.
|
|
[3]
|
Liu, J., Zhang, S., Wang, Q., et al. (2016) Seroepidemiology of Hepatitis B Virus Infection in 2 Million Men Aged 21-49 Years in Rural China: A Population-Based, Cross-Sectional Study. The Lancet Infectious Diseases, 16, 80-86. [Google Scholar] [CrossRef]
|
|
[4]
|
Cui, F., Shen, L., Li, L., et al. (2017) Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. Emerging Infectious Diseases, 23, 765-772. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Papatheodoridis, G.V., Chan, H.L., Hansen, B.E., et al. (2015) Risk of Hepatocellular Carcinoma in Chronic Hepatitis B: Assessment and Modification with Current Antiviral Therapy. Journal of Hepatology, 62, 956-967. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Kim, W.R. (2018) Emerging Therapies toward a Functional Cure for Hepatitis B Virus Infection. Gastroenterology & Hepatology (NY), 14, 439-442.
|
|
[7]
|
Levrero, M., Subic, M., Vil-leret, F., et al. (2018) Perspectives and Limitations for Nucleo(t)side Analogs in Future HBV Therapies. Current Opinion in Virology, 30, 80-89. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Trépo, C., Chan, H.L. and Lok, A. (2014) Hepatitis B Virus Infection. The Lancet, 384, 2053-2063. [Google Scholar] [CrossRef]
|
|
[9]
|
Jia, F., Deng, F., Tong, S., et al. (2020) Efficacy of Oral An-tiviral Drugs to Prevent Mother-to-Child Transmission of Hepatitis B Virus: A Network Meta-Analysis. Hepatology In-ternational, 14, 338-346. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Ren, P., Cao, Z., Mo, R., et al. (2018) Interferon-Based Treat-ment Is Superior to Nucleos(t)ide Analog in Reducing HBV-Related Hepatocellular Carcinoma for Chronic Hepatitis B Patients at High Risk. Expert Opinion on Biological Therapy, 18, 1085-1094. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Hall, S.A.L., Vogrin, S., Wawryk, O., et al. (2022) Discon-tinuation of Nucleot(s)ide Analogue Therapy in HBeAg- Negative Chronic Hepatitis B: A Meta-Analysis. Gut, 71, 1629-1641.
|
|
[12]
|
中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版) [J]. 中华临床感染病杂志, 2022, 15(6): 401-427.
|
|
[13]
|
中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 慢性乙型肝炎基层诊疗指南(2020年) [J]. 中华全科医师杂志, 2021, 20(2): 13.
|
|
[14]
|
林彬彬, 张道森, 肖志鸿, 等. HBeAg阴性慢性乙型肝炎患者恩替卡韦经治后联合应用长效干扰素的疗效研究[J]. 中西医结合肝病杂志, 2020, 30(4): 296-299+325.
|
|
[15]
|
Pan, C.Q., Li, M.-H., Yi, W., et al. (2021) Outcome of Chinese Patients with Hepatitis B at 96 Weeks after Functional Cure with IFN versus Combination Regimens. Liver International, 41, 1498-1508. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Cheng, K., Chen, Y., Wang, X., et al. (2022) Entecavir Combined with In-terferon-α Is Superior to Entecavir Monotherapy in Reducing Hepatic and Extrahepatic Cancer in Patients with Chronic Hepatitis B. Cancer, 128, 558-569. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Hauptstein, N., Meinel, L. and Lühmann, T. (2022) Bioconjugation Strate-gies and Clinical Implications of Interferon- Bioconjugates. European Journal of Pharmaceutics and Biopharmaceutics, 172, 157-167. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
金丽, 苏强, 周建华, 等. Ⅰ型和Ⅲ型干扰素抗病毒作用机制的研究进展[J]. 中国生物制品学杂志, 2021, 34(4): 481-486.
|
|
[19]
|
Park, E.J., Choi, J., Lee, K.C., et al. (2019) Emerging PEGylated Non-Biologic Drugs. Expert Opinion on Emerging Drugs, 24, 107-119. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
邱锋, 魏书德. 聚乙二醇干扰素α-2a治疗HBeAg阴性慢性乙型肝炎的疗效及影响因素[J]. 吉林医学, 2019, 40(1): 9-11.
|
|
[21]
|
Mao, Q.-G., Liang, H.-Q., Yin, Y.-L., et al. (2022) Comparison of Interferon-α-Based Therapy and Nucleos(t)ide Analogs in Preventing Adverse Outcomes in Pa-tients with Chronic Hepatitis B. Clinics and Research in Hepatology and Gastroenterology, 46, Article ID: 101758. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Viganò, M., Invernizzi, F., Grossi, G., et al. (2016) Review Arti-cle: The Potential of Interferon and Nucleos(t)ide Analogue Combination Therapy in Chronic Hepatitis B Infection. Ali-mentary Pharmacology & Therapeutics, 44, 653-661. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Xu, W., Li, Q., Huang, C., et al. (2021) Efficacy of Peg-Interferon-Nucleoside Analog Sequential Optimization Therapy in HBeAg-Positive Patients with CHB. Hepatology International, 15, 51-59. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Qi, W.Q., Zhang, Q., Wang, X., et al. (2021) Long-Term Clini-cal Benefit of Peg-IFNα and NAs Sequential Anti-Viral Therapy on HBV Related HCC. Neoplasma, 68, 200-207. [Google Scholar] [CrossRef]
|
|
[25]
|
Enomoto, M., Nishiguchi, S., Tamori, A., et al. (2018) Se-quential Therapy Involving an Early Switch from Entecavir to Pegylated Interferon-α in Japanese Patients with Chronic Hepatitis B. Hepatology Research, 48, 459-468. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Huang, D., Yan, W., Han, M., et al. (2022) Insufficient Immunity Led to Virologic Breakthrough in NAs-Treated Chronic Hepatitis B Patients Switching to Peg-IFN-α. Antiviral Research, 197, Article ID: 105220. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Hoa, P.T., Huy, N.T., Thu Le, T., et al. (2009) Randomized Controlled Study Investigating Viral Suppression and Serological Response Following pre-S1/pre-S2/S Vaccine Therapy Combined with Lamivudine Treatment in HBeAg- Positive Patients with Chronic Hepatitis B. Antimicrobial Agents and Chemotherapy, 53, 5134-5140. [Google Scholar] [CrossRef]
|
|
[28]
|
Ghozy, S., Nam, N.H., Radwan, I., et al. (2020) Therapeutic Efficacy of Hepatitis B Virus Vaccine in Treatment of Chronic HBV Infections: A Systematic Review and Meta-Analysis. Re-views in Medical Virology, 30, e2089. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Yeh, M.L., Huang, J.F., Dai, C.Y., et al. (2019) Pharmacokinetics and Pharmacodynamics of Pegylated Interferon for the Treatment of Hepatitis B. Expert Opinion on Drug Metabolism & Toxicology, 15, 779-785. [Google Scholar] [CrossRef] [PubMed]
|